Senate backs rare‑disease advisory council, adds long‑COVID resources

The Senate heard testimony and committee reports in support of H46, which would create a Rare Disease Advisory Council within the Department of Health. Committee presenters described gaps in Vermont's rare‑disease care — fragmented services, limited provider awareness and no mechanism for lived‑experience input — and said the council would elevate patient voices, coordinate policy recommendations and support diagnostics and provider resources.

The bill calls for a membership that includes two individuals living with a rare disease, a parent or guardian, the commissioner of health or a designee, representatives from health equity and clinical communities, researchers, practicing clinicians (physician, nurse, pharmacist) and a geneticist or genetic counselor. The council would be appointed to staggered five‑year terms and may convene hearings, provide recommendations to the legislature and collaborate with national organizations such as the National Organization for Rare Disorders.

Section 3 in the bill directs the Department of Health to develop long‑COVID resources for primary‑care providers and patients in collaboration with the University of Vermont Medical Center, Vermont Medical Society and patients with lived experience; the department must report recommendations to relevant committees by February 1, 2027. Committees on Health & Welfare and Appropriations reported support (committee votes 5–0 and 7–0 respectively), and the Senate ordered third reading.

A member of the public with lived experience and a medical background provided poignant testimony read into the record describing the personal and administrative burdens families face, urging passage to use lived experience in policy formation.